Objective-Cellular fibronectin containing extra domain A (EDA + -FN) is abundant in the arteries of patients with atherosclerosis. Several in vitro studies suggest that EDA + -FN interacts with Toll-like receptor 4 (TLR4). We tested the hypothesis that EDA + -FN exacerbates atherosclerosis through TLR4 in a clinically relevant model of atherosclerosis, the apolipoprotein E-deficient (Apoe −/− ) mouse. Approach and Results-The extent of atherosclerosis was evaluated in whole aortae and cross sections of the aortic sinus in male and female EDA −/− Apoe −/− mice (which lack EDA + -FN), EDA fl/fl Apoe −/− mice (which constitutively express EDA + -FN), and control Apoe −/− mice fed a high-fat Western diet for 14 weeks. Irrespective of sex, EDA fl/fl Apoe −/− mice exhibited a 2-fold increase in atherosclerotic lesions (aorta and aortic sinus) and macrophage content within plaques, whereas EDA −/− Apoe −/− mice exhibited reduced atherosclerotic lesions (P<0.05 versus Apoe −/− , n=10-12 mice/group), although cholesterol and triglyceride levels and circulating leukocytes were similar. Genetic ablation of TLR4 partially reversed atherosclerosis exacerbation in EDA fl/fl Apoe −/− mice (P<0.05) but had no effect on atherosclerotic lesions in EDA −/− Apoe −/− mice. Purified cellular FN, which contains EDA, potentiated dose-dependent NFκB-mediated inflammation (increased phospho-NFκB p65/NFκB p65, tumor necrosis factor-α, and interleukin-1β) in bone marrow-derived macrophages from EDA −/− Apoe −/− mice but not from EDA −/− TLR4 −/− Apoe −/− mice. Finally, using immunohistochemistry, we provide evidence for the first time that EDA + -FN colocalizes with macrophage TLR4 in murine aortic lesions and human coronary artery atherosclerotic plaques. Conclusions-Our findings reveal that TLR4 signaling contributes to EDA + -FN-mediated exacerbation of atherosclerosis.
A therosclerosis is a chronic inflammatory disease that affects large arteries and is characterized by plaques composed of lipids, calcium, extracellular matrix (ECM), and inflammatory cells, including monocytes/macrophages, T lymphocytes, and neutrophils. Much of the morbidity and mortality associated with atherosclerosis is as a result of coronary artery plaques, which cause luminal obstruction because of vessel stenosis and occlusive thrombus triggered by rupture of unstable plaques. During progression of atherosclerosis, extensive remodeling of ECM takes place. Several studies have found that altered ECM participates at different stages of atherosclerosis. 1, 2 There is emerging evidence that in chronically inflamed tissues, aberrant expression of ECM proteins or ECM fragments can modulate migration of leukocytes and immune cell responses at these sites. 3 In healthy human arteries, the endothelium resides on an ECM that is mainly composed of collagen type IV and laminin. In contrast, the ECM of atherosclerotic arteries contains abundant deposits of fibronectin (FN) in both humans and murine models, [4] [5] [6] [7] suggesting a functional role for FN in the pathophysiology of atherosclerosis.
FN is a dimeric glycoprotein that is known to play an important role in several cellular processes. 8 FN exhibits diversity at the protein level as a consequence of alternative splicing of a single primary transcript at 3 exons that encode the extra domain A (EDA), the extra domain B, and the Type III homologies connecting segment. The major isoform of FN found in plasma lacks both the alternatively spliced EDA and extra domain B segments and is synthesized by hepatocytes. The predominant isoform of FN found in the ECM, which is known as cellular FN (cFN), contains the EDA or extra domain B segments or both. cFN in the ECM is synthesized by vascular cells, including endothelial and vascular muscle cells. 8 The amino acid sequence of the EDA is highly conserved (>90%) in mammals, as is its splicing pattern, with either total inclusion or exclusion of the EDA observed in mice, rats, and humans. 9 Inclusion of the EDA exon in FN gene by alternative splicing is specifically regulated during several biological and pathological processes, including cutaneous wound healing, 10, 11 vascular intimal proliferation, 12 vascular hypertension, 13 cardiac transplantation, 14 and fibrosis of the lung, liver, and kidney, [15] [16] [17] suggesting a functional role for cFN containing EDA (EDA + -FN) in these biological processes.
EDA + -FN are specifically expressed in atherosclerotic but not healthy arteries, suggesting a possible functional role for EDA + -FN in atherosclerosis. 12, 18 Two prior studies have found that deletion of the EDA exon of the FN gene reduces atherosclerotic plaque progression in mice, 18, 19 but the mechanisms underlying these observations remain obscure. In vitro studies have suggested that EDA, but not other domains of FN, activates Toll-like receptor 4 (TLR4) signaling. 20 In agreement with this finding, our group reported recently that a pharmacological inhibitor of TLR4 (TAK-242) prevented the ability of EDA + -FN to exacerbate ischemia/reperfusion injury in the brain. 21 Recently, it was shown that EDA + -FN interacts with TLR4 and promotes chronic cutaneous fibrosis through TLR4 signaling. 22 Given that TLR4 is known to modulate progression of atherosclerosis, 23 these findings provided a compelling rationale to test the hypothesis that EDA + -FN promotes atherosclerosis through the TLR4 signaling pathway. We generated following strains of atherosclerotic apolipoprotein E-deficient (Apoe −/− ) mice: (1) EDA fl/fl Apoe −/− mice, which constitutively express EDA + -FN; (2) EDA −/− Apoe −/− mice, which completely lack EDA + -FN; (3) EDA fl/fl TLR4 −/− Apoe −/− mice, which constitutively express EDA + -FN but lack TLR4; (4) EDA −/− TLR4 −/− Apoe −/− mice, which lack EDA + -FN and TLR4; (5) TLR4 −/− Apoe −/− mice, which lack TLR4; and (6) control Apoe −/− mice, which express low levels of EDA + -FN, as well as other FN splicing variants.
Herein, we provide evidence for the first time that TLR4 contributes to EDA + -FN-mediated atherosclerosis exacerbation in Apoe −/− mice. Furthermore, we show that EDA + -FN colocalizes with TLR4 on macrophages in murine aortic lesions and human coronary atherosclerotic plaques.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Constitutive Expression of EDA + -FN Promotes Progression of Atherosclerosis, Whereas Deletion of EDA Protects Against Atherosclerosis, in Apoe −/− Mice
To determine the functional role of EDA + -FN in atherosclerosis, we generated several novel mutant strains of Apoe −/− mice as described in Materials and Methods. Both male and female EDA −/− Apoe −/− mice (which lack EDA + -FN), EDA fl/fl Apoe −/− mice (which constitutively express EDA + -FN), and control Apoe −/− mice were first fed a chow diet for 6 weeks and then a high-fat Western diet for 14 weeks. Using ELISA, we first measured plasma levels of EDA + -FN. As expected at baseline, EDA + -FN was absent in the plasma of EDA −/− Apoe −/− mice and elevated by 3-fold in EDA fl/fl Apoe −/− mice compared with Apoe −/− mice (P<0.05; Table I in the online-only Data Supplement). Plasma levels of EDA + -FN increased progressively after 14 weeks of high-fat Western diet in both Apoe −/− and EDA fl/fl Apoe −/− mice but remained significantly higher in EDA fl/fl Apoe −/− mice compared with Apoe −/− mice (P<0.05, Table I in the online-only Data Supplement). Irrespective of sex, plasma cholesterol and triglyceride levels were similar in the EDA −/− Apoe −/− , EDA fl/fl Apoe −/− , and Apoe −/− mice fed a high-fat diet for 14 weeks (Table) , suggesting that inclusion or deletion of EDA in FN does not affect plasma lipid levels. Next, we compared the extent of atherosclerosis in whole aortae by staining with Oil Red O and quantifying en face lesion area. Both male and female EDA fl/fl Apoe −/− mice exhibited significantly larger lesion areas, whereas male and female EDA −/− Apoe −/− exhibited significantly reduced lesion areas compared with male and female Apoe −/− mice (P<0.05, N=10-12 mice/group, Figure 1A and 1B). Next, we quantified the cross-sectional area of atherosclerotic lesions in the aortic sinus using the VerHoeffs/Van Gieson staining method. We found that the mean lesion areas in the aortic sinus of both male and female EDA fl/fl Apoe −/− mice were significantly larger when compared with those of Apoe −/− mice (P<0.05, Figure 1C and 1D). Conversely, male and female EDA −/− Apoe −/− mice exhibited significantly reduced lesion areas when compared with Apoe −/− mice (P<0.05, N=10-12 mice/group; Figure 1C and 1D). Next, we measured the interstitial collagen content. Picrosirius red staining of lesions in the aortic sinus revealed similar collagen content ( Figure I Constitutive expression of EDA + -FN increases macrophage infiltration within atherosclerotic plaques of Apoe −/− mice, whereas deletion of EDA reduces plaque inflammation.
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To determine whether EDA + -FN enhances inflammatory cell recruitment to atherosclerotic plaques, we quantified macrophage infiltration (Mac3-positive area) within plaques of the aortic sinus by immunohistochemistry in mice fed a high-fat diet for 14 weeks. EDA fl/fl Apoe −/− mice exhibited significant increase in absolute Mac3-positive area, as well as % of total lesion area covered by Mac3positive cells, whereas EDA −/− Apoe −/− mice had significantly reduced Mac3-positive area when compared with Apoe −/− mice (P<0.05; Figure 2A ). Total leukocyte counts were similar among genotypes ( Table II in 
Exogenous EDA + -FN Promotes Uptake of Native Low-Density Lipoprotein Complexes Containing Heparin and Collagen
To determine whether there was a difference in uptake of modified low-density lipoprotein (LDL) by macrophages, we incubated bone marrow-derived macrophages from EDA fl/fl Apoe −/− , EDA −/− Apoe −/− , and Apoe −/− mice with acetylated LDL and then stained with Oil Red O. We found that foam cell formation and acetylated LDL uptake was comparable among EDA fl/fl Apoe −/− , EDA −/− Apoe −/− , and Apoe −/− mice after 24 hours ( Figure 2B ). Additionally, foam cell formation and acetylated LDL uptake was comparable in EDA −/− Apoe −/− macrophages treated either in presence or absence of exogenous human cFN, which contains EDA (EDA + -FN; Figure  III in the online-only Data Supplement). Previous in vitro studies have suggested that FN interaction with other ECM proteins, such as collagen and glycosaminoglycans, may enhance uptake of LDL. 24, 25 Therefore, we determined whether LDL complexes (native LDL-collagen-heparin) accumulate more in the macrophages in the presence of cFN. Interestingly, we found a significant increase in foam cell formation and LDL complex uptake in EDA −/− Apoe −/− macrophages treated with LDL-heparin-collagen-cFN complexes compared with LDL-heparin-collagen complexes ( Figure 2C ). Foam cell formation and LDL uptake was comparable in EDA −/− Apoe −/− macrophages treated with LDL or LDL-cFN ( Figure 2C ). 
EDA + -FN Promotes Progression of Atherosclerosis Via TLR4
Because EDA + -FN interacts with TLR4 in vitro, 20 we tested the hypothesis that EDA + -FN promotes progression of atherosclerosis through the TLR4 signaling pathway. We used a genetic approach and generated Apoe −/− , EDA fl/fl Apoe −/− , and EDA −/− Apoe −/− mice on a TLR4-deficient background. Controls included Apoe −/− , EDA fl/fl Apoe −/− , and EDA −/− Apoe −/− littermates, respectively. Female mice were fed a high-fat
Western diet for 14 weeks. Deletion of TLR4 in Apoe −/− , EDA fl/fl Apoe −/− , and EDA −/− Apoe −/− mice did not alter plasma cholesterol or triglyceride levels when compared with controls (Table) . Deletion of TLR4 in EDA fl/fl Apoe −/− mice significantly reduced total lesion area in the aorta, as well as cross-sectional lesion area in the aortic sinus, compared with EDA fl/fl Apoe −/− mice (P<0.05; Figure 3A Figure 3A and 3B ). Together these results suggest that EDA + -FN requires TLR4 for atherosclerosis exacerbation. Next, using serial sections, we measured macrophage (Mac3-positive cells) infiltration within plaques of the aortic sinus by immunohistochemistry. Significant decrease in absolute Mac3-positive area and % of total lesion area covered by Mac3-positive cells were observed in EDA fl/fl TL R4 −/− Apoe −/− mice compared with control EDA fl/fl Apoe −/− mice (P<0.05, Figure 3C ). Mac3-positive area was significantly decreased in TLR4 −/− Apoe −/− mice compared with Apoe −/− mice (P<0.05; Figure 3C ). No significant differences in Mac3positive area were observed between EDA −/− TLR4 −/− Apoe −/− and EDA −/− Apoe −/− mice ( Figure 3C ).
EDA + -FN Promotes NFκB p65-Mediated Inflammation in Bone Marrow-Derived Macrophages
We next determined whether the interactions of exogenous EDA + -FN and TLR4 upregulate canonical NFκB p65 signaling. Bone marrow-derived macrophages from EDA −/− Apoe −/− and EDA −/− TLR4 −/− Apoe −/− mice were stimulated for 24 hours in the presence of human cFN (cFN; 0-50 μg/mL), which contains the EDA. We then measured levels of phospho-NFκB p65 and NFκB p65 in cell lysates and the inflammatory cytokines TNF-α and IL-1β in medium. At doses of 5, 10, and 50 μg/mL of cFN, immunoblotting experiments revealed a significant linear increase in phospho-NFκB p65/total NFκB p65 levels in cFN-treated macrophages from EDA −/− Apoe −/− compared with control (P<0.05; Figure 4A ). These differences were not observed in macrophages from EDA −/− TLR4 −/− Apoe −/− mice. Concomitantly, TNF-α and IL-1β protein levels were significantly increased in cFN-treated macrophages from EDA −/− Apoe −/− , but not from EDA −/− TLR4 −/− Apoe −/− mice, when compared with controls ( Figure 4B and 4C) . To exclude the possibility that the in vitro effects were simply mediated by loss of TLR4, bone marrow-derived macrophages from EDA −/− Apoe −/− and EDA −/− TLR4 −/− Apoe −/− mice were activated with a subthreshold dose (20 ng/mL) of phorbol myristate acetate for 24 hours in the presence or absence of exogenous EDA + -FN (10 μg/mL). Again, we found a significant increase in phospho-NFκB p65/total NFκB p65, TNF-α, and IL-1β protein levels in cFN-treated bone marrow-derived macrophages from EDA −/− Apoe −/− mice compared with untreated control EDA −/− Apoe −/− mice ( Figure IV in the online-only Data Supplement). Phospho-NFκB p65/total NFκB p65, TNF-α, and IL-1β protein levels were comparable in phorbol myristate acetate-treated EDA −/− TLR4 −/− Apoe −/− and EDA −/− Apoe −/− macrophages, which strongly suggests that the observed in vitro effects were not simply mediated by TLR4 deletion, but rather by a specific effect of EDA + -FN ( Figure IV in the online-only Data Supplement).
EDA + -FN Colocalizes With TLR4 on Macrophages in Human and Mice Atherosclerotic Plaques
To determine whether EDA + -FN colocalizes with TLR4 on macrophages within human atherosclerotic plaques, we performed triple-labeling fluorescent immunostaining of autopsy samples from patients with coronary artery disease. In agreement with previous reports, 6,18 EDA + -FN was abundantly expressed within human coronary artery atherosclerotic lesions ( Figure 5A-5F ). Immunostaining revealed marked infiltration of Mac3-and TLR4-positive cells within the lesions, whereas staining was virtually absent in controls (P<0.0001, N=4/ group, Pearson's correlation; Figure 5 ). Double-labeling immunostaining showed that EDA + -FN colocalizes with both TLR4 ( Figure 5D ) and macrophages ( Figure 5F ). Triple-labeling immunofluorescence staining for EDA + -FN, macrophages, and TLR4 suggested that EDA + -FN colocalizes with TLR4 expressed on macrophages ( Figure 5A-5C ). Similarly, we found colocalization of EDA + -FN with TLR4 on macrophages within aortic lesions of Apoe −/− mice fed a high-fat Western diet for 14 weeks (Figure 6 ).
Discussion
Although hypercholesterolemia remains a major risk factor for progression of atherosclerosis and a major therapeutic target, chronic inflammation is a critical contributor to the development of atherosclerosis. Moreover, it is widely accepted that both adaptive and innate immune receptors, such as TLR4, are known to mediate progression of atherosclerosis by promoting inflammation. 23, 26, 27 We, herein, provide evidence for the first time that EDA + -FN, a variant of FN that contains the alternatively spliced EDA domain, colocalizes with TLR4 and macrophages within human coronary artery plaques and aortic lesions in atheroprone Apoe −/− mice. Furthermore, using several novel mutant strains of Apoe −/− mice, we showed that EDA + -FN promotes atherosclerosis exacerbation partially through TLR4. Despite previous evidence suggesting that EDA + -FN is proatherogenic, 18, 19 the precise mechanism by which (E, H, K) , and EDA + -FN-Mac3 (F, I, L). Colocalized pixels are defined as those whose intensity values for both channels fell within a preset range above the background intensity level (white arrows as shown in D). The field of view in a control tissue section (G-I) is at a comparable location relative to the vessel lumen. J-L, Colocalization (Pearson's correlation, 1=complete colocalization). N=4/condition. November 2015 EDA + -FN promotes atherosclerosis was unclear. Tan et al proposed that reduced atherosclerosis in EDA −/− Apoe −/− mice fed a high-fat Western diet for 8, 12, and 16 weeks may be because of decreased total plasma cholesterol, but the differences in cholesterol levels reported were modest. 18 In another study in which atherosclerosis was induced by an atherogenic diet containing sodium cholate, Babaev et al reported reduced atherosclerosis in both EDA −/− mice and EDA fl/fl mice compared with wild-type (C57BL/6J) mice. However, no significant differences in total cholesterol or triglyceride levels were observed between EDA −/− mice and EDA fl/fl mice fed the atherogenic diet for 8, 14, or 18 weeks. 19 Because genetically induced atherosclerosis mouse models, such as the Apoe −/− mouse, are considered to be more clinically relevant and reproducible, we generated EDA −/− mice and EDA fl/fl mice on Apoe −/− genetic background. Irrespective of the sex, we found significantly reduced atherosclerosis in the aorta and aortic sinus of EDA −/− Apoe −/− mice (which lack EDA + -FN) and exacerbated atherosclerosis in EDA flf/fl Apoe −/− mice (which constitutively express EDA + -FN) when compared with control Apoe −/− mice. However, plasma cholesterol and triglyceride levels were similar among EDA −/− Apoe −/− , EDA fl/fl Apoe −/− , and Apoe −/− mice. Together, these results suggest that atherosclerosis exacerbation in EDA fl/fl Apoe −/− mice was not because of altered plasma cholesterol and triglyceride levels but rather because of an alternative mechanism. Indeed, several murine studies have shown that increased atherosclerotic lesions do not always correlate with plasma cholesterol and LDL levels. [28] [29] [30] Chronic inflammation triggered by the innate immune system is recognized as a key driving force for progression of atherosclerosis. 31 Our studies show that EDA + -FN promotes macrophage infiltration within atherosclerotic plaques of the aortic sinus. Intracellular and extracellular compartments contribute to lipid deposition within atherosclerotic lesions. In animal models and in humans, it is known that, within atherosclerotic lesions, monocyte-derived macrophages can take up modified extracellular lipids, thereby resulting in increased lipid deposition in the vessel wall. 27 In our studies with bone marrow-derived macrophages, we found that uptake of modified lipoproteins was comparable in EDA fl/fl Apoe −/− , EDA −/− Apoe −/− , and Apoe −/− mice. However, the in vivo microenvironment within the lesions in which macrophages reside is completely different compared with isolated cells. We hypothesize that the presence of EDA + -FN in the arterial wall in combination with collagen and glycosaminoglycans may enhance uptake of LDL by macrophages within the lesions. Indeed, we found that exogenous cFN enhanced macrophage uptake of LDL-heparin-collagen complexes. Our findings are in agreement with previous observations that LDL when incubated with heparin, FN, and collagen is avidly taken by macrophages. 24, 25 Because the protein components that were used to make LDL complexes are present in the vascular wall, we suggest that EDA + -FN may potentiate foam cell formation during atherogenesis. We speculate that this could be one of the mechanisms by which EDA fl/fl Apoe −/− mice are proatherogenic, independent of alterations in plasma cholesterol or lipid levels. Herein, we also showed for the first time the role of TLR4 in EDA + -FN-mediated atherosclerosis exacerbation. Previously, it was demonstrated that the EDA, but not other domains, of FN activates human TLR4 expressed in HEK293 (humam embryonic kidney) cells, which normally lack TLR4. 20 Like lipopolysaccharide, EDA activation of TLR4 requires MD-2 (myeloid differentiation factor-2), an accessory protein associated with extracellular domain A of TLR4 and required for TLR4-dependent lipopolysaccharide response. 20 We now provide in vivo evidence that EDA + -FN promotes progression of atherosclerosis through a mechanism that is partially dependent on TLR4. Multiple endogenous ligands (eg, heat-shock proteins, fibrinogen, and fibrin) have been shown to activate TLR4 and generate an inflammatory response. We found that TLR4 deficiency in EDA fl/fl Apoe −/− or Apoe −/− mice significantly reduced lesion progression, concomitant with decreased infiltration of macrophages within the aortic sinus, although plasma cholesterol and triglyceride levels were comparable. Our results are consistent with findings from other groups who have shown that the atheroprotective effects of MyD88 or TLR4 deficiency are not because of altered serum cholesterol or lipoproteins but rather to reduced inflammation. 23 Of note, TLR4 deficiency did not significantly alter lesion size in EDA −/− Apoe −/− mice suggest that EDA + -FN could be one of the major endogenous ligands that promotes atherogenesis through the TLR4 signaling pathway.
TLR4 is expressed on multiple cell types that might contribute to the proatherogenic role of EDA + -FN. Herein, using bone marrow-derived macrophages, we demonstrate that exogenous cFN potentiated the phosphorylation of NFκB p65, which is a component of the canonical signaling pathway downstream of TLR4 and has been reported to promote atherosclerosis. 32 Our in vitro studies support a mechanistic model in which lesion macrophages, through TLR4, interact with EDA + -FN in the ECM and, thereby, promote inflammatory response that may then amplify the inflammatory microenvironment within atherosclerotic lesions by promoting additional monocyte entry. Although our in vitro mechanistic studies suggest a role for TLR4 on macrophages that may contribute to EDA + -FN-mediated inflammation and, thereby, atherosclerosis exacerbation, additional murine studies using either endothelial-or bone marrow-specific deletion of TLR4 will be required to define the specific cell types responsible for the TLR4-dependent effects of EDA + -FN on atherosclerosis in vivo. Finally, we provide evidence for the first time that EDA + -FN colocalizes with TLR4 on macrophages within human coronary atherosclerotic plaques and in murine aortic lesions. Although our studies indicate that TLR4 signaling significantly contributes to EDA + -FN-mediated inflammation during atherosclerosis, it remains possible that some of the proinflammatory effects of EDA + -FN are TLR4-independent, perhaps mediated by binding sites for leukocyte integrins α4β1 and α9β1 in the EDA domain. 33 Additional studies will be required to determine whether disruption of EDA + -FNintegrin interactions in vivo prevents monocyte recruitment and subsequent atherosclerotic lesion progression.
In summary, our studies unequivocally demonstrate that EDA + -FN is proatherogenic in mouse models of atherosclerosis. Importantly, we provide genetic evidence for the first time that EDA + -FN/TLR4 signaling enhances recruitment of monocytes/macrophages into developing plaques, thereby promoting progression of atherosclerosis. The abundant expression of EDA + -FN in human atherosclerotic plaques and the mechanistic insights provided by the current study may open new arenas for the prevention and treatment of atherosclerosis in patients at high risk for coronary heart disease.
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